Katerina Katsaraki

Ms. Katerina Katsaraki

National and Kapodistrian University of Athens, Department of Biology
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Katerina KatsarakiKaterina Katsaraki
Katerina Katsaraki
Paraskevi KarousiParaskevi Karousi
Paraskevi Karousi
Pinelopi ArtemakiPinelopi Artemaki
Pinelopi Artemaki
ASAndreas Scorilas
Andreas Scorilas
VPVasiliki Pappa
Vasiliki Pappa
SPSotirios Papageorgiou
Sotirios Papageorgiou
MicroRNAs (miRNAs) represent a class of small non-coding RNAs bearing regulatory potency. The implication of miRNAs in physiological cellular processes has been well documented so far. A typical process orchestrated by miRNAs is the normal B-cell development. A stage-specific expression pattern of miRNAs has been reported in the developmental procedure, as well as interactions with transcription factors that dictate B-cell development. Besides their involvement in normal hematopoiesis, miRNAs are severally implicated in hematological malignancies, a typical paradigm of which is B-cell chronic lymphocytic leukemia (B-CLL). B-CLL is a highly heterogeneous disease characterized by the accumulation of abnormal B cells in blood, bone marrow, lymph nodes, and spleen. Therefore, timely, specific, and sensitive assessment of the malignancy is vital. Several studies have attempted to highlight the remarkable significance of miRNAs as regulators of gene expression, biomarkers for diagnosis, prognosis, progression, and therapy response prediction, as well as molecules with potential therapeutic utility. This review seeks to outline the linkage between miRNA function in normal and malignant hematopoiesis by demonstrating the main benchmarks of the implication of miRNAs in the regulation of normal B-cell development, and to summarize the key findings about their value as regulators, biomarkers, or therapeutic targets in B-CLL.

4 April 2019 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
Paraskevi KarousiParaskevi Karousi
Paraskevi Karousi
Katerina KatsarakiKaterina Katsaraki
Katerina Katsaraki
SPSotirios Papageorgiou
Sotirios Papageorgiou
VPVasiliki Pappa
Vasiliki Pappa
ASAndreas Scorilas
Andreas Scorilas
Christos KontosChristos Kontos
Christos Kontos


25 March 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Pinelopi ArtemakiPinelopi Artemaki
Pinelopi Artemaki
PLPetros Letsos
Petros Letsos
Zoupa IoannaZoupa Ioanna
Zoupa Ioanna
Katerina KatsarakiKaterina Katsaraki
Katerina Katsaraki
Paraskevi KarousiParaskevi Karousi
Paraskevi Karousi
Christos KontosChristos Kontos
Christos Kontos
Normal B-cell development is a tightly regulated complex procedure, the deregulation of which can lead to lymphomagenesis. One common group of blood cancers is the B-cell non-Hodgkin lymphomas (NHLs), which can be categorized according to the proliferation and spread rate of cancer cells into indolent and aggressive ones. The most frequent indolent B-cell NHLs are follicular lymphoma and marginal zone lymphoma. MicroRNAs (miRNAs) are small non-coding RNAs that can greatly influence protein expression. Based on the multiple interactions among miRNAs and their targets, complex networks of gene expression regulation emerge, which normally are essential for proper B-cell development. Multiple miRNAs have been associated with B-cell lymphomas, as the deregulation of these complex networks can lead to such pathological states. The aim of the present review is to summarize the existing information regarding the multifaceted role of miRNAs in indolent B-cell NHLs, affecting the main B-cell subpopulations. We attempt to provide insight into their biological function, the complex miRNA-mRNA interactions, and their biomarker utility in these malignancies. Lastly, we address the limitations that hinder the investigation of the role of miRNAs in these lymphomas and discuss ways that these problems could be overcome in the future.


24 June 2022 in Genes
Verified
Journal Article
Open access
PDF file
Maria PapatsirouMaria Papatsirou
Maria Papatsirou
Marios A. DiamantopoulosMarios A. Diamantopoulos
Marios A. Diamantopoulos
Katerina KatsarakiKaterina Katsaraki
Katerina Katsaraki
Dimitris KletsasDimitris Kletsas
Dimitris Kletsas
Christos KontosChristos Kontos
Christos Kontos
ASAndreas Scorilas
Andreas Scorilas
Circular RNAs (circRNAs) constitute a type of RNA formed through back-splicing. In breast cancer, circRNAs are implicated in tumor onset and progression. Although histone methylation by PRMT1 is largely involved in breast cancer development and metastasis, the effect of circular transcripts deriving from this gene has not been examined. In this study, total RNA was extracted from four breast cancer cell lines and reversely transcribed using random hexamer primers. Next, first- and second-round PCRs were performed using gene-specific divergent primers. Sanger sequencing followed for the determination of the sequence of each novel PRMT1 circRNA. Lastly, bioinformatics analysis was conducted to predict the functions of the novel circRNAs. In total, nine novel circRNAs were identified, comprising both complete and truncated exons of the PRMT1 gene. Interestingly, we demonstrated that the back-splice junctions consist of novel splice sites of the PRMT1 exons. Moreover, the circRNA expression pattern differed among these four breast cancer cell lines. All the novel circRNAs are predicted to act as miRNA and/or protein sponges, while five circRNAs also possess an open reading frame. In summary, we described the complete sequence of nine novel circRNAs of the PRMT1 gene, comprising distinct back-splice junctions and probably having different molecular properties.